tbuckley/cabot-search huggingface dataset:
Radiocontrast-Induced Acute Renal Failure—Impact beyond the Acute Phase
Authors: Dangas G., Iakovou I., Nikolsky E., Aymong E.D., Mintz G.S., Kipshidze N.N., Lansky A.J., Moussa I., Stone G.W., Moses J.W., Leon M.B., Mehran R.
Journal: Journal of the American Society of Nephrology (2006)

Radiocontrast-induced nephropathy is a well known consequence of cardiologic interventions. Acute radiocontrast nephropathy is the third most common cause of acute renal failure in patients admitted to a hospital ([1][1]). Up to 7% of patients with this condition need temporary dialysis or progress
Predictability of the survival of patients with advanced ovarian cancer.
Authors: J C van Houwelingen, W W ten Bokkel Huinink, M E van der Burg, A T van Oosterom, J P Neijt
Journal: Journal of Clinical Oncology (1989)

Based on material from two clinical trials performed by The Netherlands Joint Study Group for Ovarian Cancer, we constructed a prognostic index (PI) with considerable predictive power for long-term survival of patients treated with cytotoxic combination chemotherapy including cisplatin. The pretreatment characteristics needed for the calculation of the PI are the Karnofsky index, the site of metastases expressed as the International Federation of Gynecology and Obstetrics (FIGO) stage, the size of residual tumor, the Broders' grade, and the presence of ascites. In the subgroup comprising the 10% of the patients with the best prognosis, 4-year survival was 75%, whereas all of the patients in the subgroup comprising the 10% with the poorest prognosis died within 4 years, which illustrates the large variability of the prognosis among patients. The PI was found to retain its value after response was achieved. The information provided by the PI can be expected to be useful in treatment planning and for proper stratification of patients in clinical trials.
Abstract 14782: Effect of CD40 and sCD40L on Renal Function and Survival in Patients with Renal Artery Stenosis
Authors: Steven T Haller, Philip A Kalra, James P Ritchie, Tina Chrysochou, Pamela Brewster, Wencan He, Haifeng Yu, Suohong Wang, Joseph I Shapiro, Christopher J Cooper
Journal: Circulation (2012)
Overview: psychiatric sequelae to multiple trauma
Authors: N Schnaper, R A Cowley
Journal: American Journal of Psychiatry (1976)

The authors discuss the setting, patients, and staff, and the role of psychiatric consultants in intensive care units and trauma centers. They point out the similarities and differences between patients with multiple trauma and those who have had open-heart surgery and head or spinal cord injuries. They also deal with the question of an element of self-destructive behavior in accidents and offer suggestions for the psychiatric management of severely traumatized patients. The authors conclude that the role and obligation of the psychiatrist of the the future will lie in crisis intervention within the medical-biological model.
Determinants of Peanut Allergy in an Observational Study (CoFAR2) of Food Allergy
Authors: Scott H. Sicherer, Robert A. Wood, Tamara T. Perry, Brian P. Vickery, Stacie M. Jones, Donald Y. Leung, Beth Blackwell, Peter Dawson, A. Wesley Burks, Robert W. Lindblad, Hugh A. Sampson
Journal: Journal of Allergy and Clinical Immunology (2016)
Abstract 13136: MiR-320 as Potential Biomarker of Arrhythmogenic Right Ventricular Cardiomyopathy
Authors: Elena Sommariva, Yuri D’Alessandra, Silvia Brambilla, Fabio Cattaneo, Michela Casella, Maurizio C Capogrossi, Claudio Tondo, Giulio Pompilio
Journal: Circulation (2014)

Rationale: Diagnosis of Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC) is challenging and often late after disease onset. MicroRNAs (miRNAs) have been proposed as circulating biomarkers of cardiac diseases such as heart failure, myocardial infarction and atrial fibrillation. No previous studies did evaluate the involvement of miRNAs in ARVC. Aim: Our objective was to study circulating miRNAs expression profile in ARVC and correlate results in patient’s cardiac cells. Methods: The expression of 367 miRNAs was screened in plasma samples from ARVC patients and matched healthy donors using TaqMan Arrays (n=3 symptomatic ARVC patients vs n=3 healthy subjects). Selected miRNAs were validated in the plasma of healthy subjects (n=15) and of patients with a diagnosis of ARVC as defined by current guidelines (n=14). Selected miRNA expression was then tested in cardiac stromal cells (CSCs) obtained from ventricular biopsies of ARVC and non-ARVC patients (n=3 each). Results: Among 118 miRNAs found expressed i...
Preclinical evaluation of sunitinib, alone and in combination with trastuzumab, in HER2 positive breast cancer (BC)
Authors: D. Tryfonopoulos, N. O’Donovan, M. Clynes, J. P. Crown
Journal: Journal of Clinical Oncology (2008)

14689 Background: There is a potentially therapeutically relevant interaction between the HER2 and VEGF systems. In addition to targeting VEGFR, the multi-target kinase inhibitor (TKI) sunitinib malate targets c-Kit, PDGFR, RET, FLT-3 and CSF-1R. The aim of this study was to assess the direct anti-tumour effects of sunitinib, alone and in combination with trastuzumab in HER2 positive breast cancer. Methods: A panel of HER-2 positive and HER-2 negative BC cell lines were tested with sunitinib malate and compared with imatinib mesylate, which targets Bcr-Abl, PDGFR and c-Kit. IC50s were determined using the acid phosphatase assay. HER-2 positive cell lines were treated with a combination of sunitinib and trastuzumab. Results: IC50 values were similar in the HER-2 positive and negative cell lines for both imatinib and sunitinib. All of the cell lines showed greater sensitivity to sunitinib than to imatinib. Sunitinib was tested in combination with trastuzumab in two trastuzumab sensitive cell lines (SKBR3 and BT474) and two trastuzumab-resistant cell lines (JIMT-1 and HCC-1419). Combined treatment with sunitinib and trastuzumab showed improved response compared to either drug alone, in all of the HER-2 positive cell lines tested (Table). Conclusions: Our findings suggest that sunitinib alone shows modest anti-tumour activity against breast cancer cells but shows a positive interaction with trastuzumab in HER-2 positive BC cell lines in vitro. Together with the anit-angiogenic effects of sunitinib, this combination of targeted therapies may improve response to trastuzumab in HER2 positive breast cancer. Cell Line IC50s (+ std dev) % Growth (+ std dev) Imatinib (μM) Sunitinib (μM) Sunitinib (7.5 μΜ) Trastuzumab (7.5 nΜ) Sunitinib (7.5 μΜ) + trastuzumab (7.5 nΜ) SKBR-3 14.9+2.3 5.4+0.9 45.4+5.1 65.2+5.2 33.3+4.3 JIMT-1 23.4+4.1 7.3+1.9 60.9+11.3 99.5+1.9 50.4+10.9 BT-474 17.7+3.6 5.0+1.3 57.6+6.1 39.6+6.2 20.1+10.1 HCC-1419 32.3+3.7 8.4+2.9 90.9+16.3 86.1+5.6 74.5+7.3 Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Expert Testimony Other Remuneration Pfizer Oncology, Roche
Abstract 17115: Graft versus Host Disease-associated Pericardial Disease: Incidence, Timing, and Treatment Options
Authors: Lidija B McGrath, Jessica Leonard, Shernan Holtan, Richard Maziarz, Joaquin Cigarroa, Stephen Heitner
Journal: Circulation (2013)

INTRODUCTION: Pericardial disease (PD) is a rare manifestation of chronic graft versus host disease (GVHD). Isolated cases have been reported, but risk factors, biomarkers, treatment strategies, and outcomes have never been examined.

HYPOTHESIS: GVHD-related PD is associated with the tapering of immunosuppressive therapy (IST), and aggressively treated patients fare worse than more conservative therapy.

METHODS: Patients undergoing allogeneic hematopoietic stem cell transplant (aSCT) at a single center between 1996-2012 were identified as having pericardial effusion, tamponade, or effusive-constrictive pericarditis associated with GVHD. Individual laboratory, echocardiographic, hemodynamic, and imaging findings were analyzed. Patient outcomes were assessed in relation to their presentation and the therapy chosen.

RESULTS: Of the 896 aSCT procedures, 19 met criteria for inclusion - 18 patients had pericardial effusion, 5 tamponade, and 4 effusive-constrictive pericarditis. PD occurred in the setting of recent IST taper in 12 of the 19 cases. A significant increase in blood monocytes and decrease in serum albumin were identified at diagnosis compared with pre-diagnosis. Hemodynamic and imaging findings are presented in Table 1. 17 patients were treated with steroids either alone (10) or in combination with pericardial window (4), pericardiocentesis (6), or pericardiectomy (2). Of the 8 deaths, 3 had tamponade at presentation and 3 were treated with invasive surgical procedures. Of the 10 patients with IST only, 4 died and 6 demonstrated partial or complete response.

CONCLUSIONS: GVHD-associated PD should be suspected in symptomatic patients undergoing IST taper. Most patients have characteristic findings with imaging and hemodynamic studies. Patients presenting with cardiac tamponade, hemodynamic compromise, and those treated surgically seem to fare worse when compared with conservatively treated patients.

![Graphic][1]  [1]: /embed/inline-graphic-1.gif
Late-breaking abstract: Asymmetric dependence of VO2 on ventilation-perfusion ratio
Authors: Min-Yeong Kang, Bernard Sapoval
Journal: European Respiratory Journal (2014)

Oxygen gas diffusion has been shown to condition the size of mammal's acini (Sapoval, B. et al. PNAS 2002; 99:10411-10416). Recently, the dynamical equations taking account of O2 convection, diffusion and permeation across the membrane were solved (Foucquier, A. et al. Respir. Physiol. Neurobiol. 2013; 185: 625-638). Together with this, a new dynamical equation, governing O2 diffusion in blood (including membrane, plasma and erythrocytes), gives us the acinar VO2 as a function of ventilation V and perfusion Q. When V and Q variations are normalized by their normal healthy values, Vn and Qn, our method allows us to obtain a map of VO2 dependence on V and Q. Then, VO2 depends on V and Q in a complex manner: it is not a function of V/Q only.

![Figure][1] 



When plotting VO2 as a function of V/Q, we can see clearly that VO2 dependence on Q at given V (dotted lines) is more rapid than that on V at given Q (solid lines).

![Figure][1] 



The results show that, except extreme situations, oxygen capture depends strongly on perfusion heterogeneity and weekly on ventilation heterogeneity. The same consideration can be applied to any homogeneous region consisting of identical acini and applied to during exercise also.

 [1]: pending:yes
Clinical activity of bortezomib in relapsed or refractory gastric marginal zone b-cell lymphoma of malt type
Authors: P. Spadaro, V. Pitini, G. Toscano, H. J. Soto Parra, M. Ingemi, G. Dottore, C. Arrigo, C. Buda
Journal: Journal of Clinical Oncology (2008)

8567
Nilotinib in chronic myeloid leukemia patients in accelerated phase (CML-AP) with imatinib (IM) resistance or intolerance: Longer follow-up results of a phase II study
Authors: P. D. Le Coutre, F. Giles, A. Hochhaus, J. F. Apperley, G. Ossenkoppele, A. Haque, N. J. Gallagher, M. Baccarani, J. Cortes, H. Kantarjian
Journal: Journal of Clinical Oncology (2009)

7057 Background: Nilotinib is a potent and highly selective BCR-ABL inhibitor approved for the treatment of Ph+ CML patients (pts) in chronic phase or AP who are resistant or intolerant to prior therapy including IM. This study evaluated the efficacy and safety of nilotinib (400 mg bid) in CML-AP pts resistant or intolerant to IM. Methods: Primary endpoint was confirmed hematologic response (HR). Secondary endpoints included major cytogenetic response (MCyR), time to progression, overall survival (OS), and safety. Results: 137 CML-AP pts (80% IM-resistant; 20% IM-intolerant with resistance) with minimum follow-up of 11 months (mos) (median age, 57 years; median duration of prior IM treatment, 28 mos) were included. IM-intolerant pts were also IM-resistant and without MCyR at study entry. 79% pts had prior IM ≥600 mg/day. Median dose intensity of nilotinib was 775 mg/day and median duration of exposure was 272 days. 56% had confirmed HR and 31% had complete hematologic response (CHR). 30% of IM-resistant and 37% of IM-intolerant pts achieved CHR. Responses were rapid, with a median time to first HR of 1 mo. HRs were durable at 24 mos with 54% of pts maintaining their response. MCyR was achieved in 32% of pts (30% in IM-resistant, 41% in IM-intolerant) and complete cytogenetic response in 20% of pts (18% in IM-resistant, 30% in IM-intolerant). Cytogenetic responses were also durable with 70% of pts maintaining MCyR at 24 mos; 83% of pts maintained CCyR at 12 mos. Estimated OS at 24 mos was 67%. Only 9% of pts discontinued therapy due to drug-related adverse events (AE). The most frequently reported grade 3/4 laboratory abnormalities were thrombocytopenia (41%), neutropenia (42%), anemia (25%), elevated serum lipase (18%), and hypophosphatemia (14%). The rates of grade 3/4 myelosuppression were low, predictable, and easily managed with median onset of 14 to 29 days and median duration of 8 to 26 days. Grade 3/4 non-hematologic AEs were rare (&lt; 1%) and included nausea, fatigue, and diarrhea. Conclusions: These long-term follow-up results confirm that nilotinib induces rapid and durable responses in CML-AP pts who failed prior IM due to intolerance or resistance, with a favorable risk/benefit. [Table: see text]
Growth inhibitory effect of ceramide-incorporated nanoliposomes in human pancreatic cancer cells
Authors: Y. Jiang, J. Kaiser, Y. Heakal, H. Cheng, T. Loughran, M. Kester
Journal: Journal of Clinical Oncology (2007)

14105 Background: In cancer therapy, it is a challenging task to develop an optimal therapeutic regimen with an improved drug delivery vehicle and a cancer targeting strategy. Liposome-based drug delivery vehicles have been proven feasible and effective in clinical applications. We have recently developed a novel 80 nanometer diameter liposomal formulation that incorporates 30 molar percent C6-ceramide, a lipid-derived second messenger that is proapoptotic to cancer cells, but not to normal cells. Methods: MTT assay was used to evaluate cell proliferation and viability. In vitro soft agar colony forming assay was utilized to assess the transforming activity of pancreatic cancer cell lines. For apoptosis, caspase 3/7 assay was applied. Results: We assessed the biological effect of C6-ceramide nanoliposomes (C6 liposome) in two human pancreatic cancer cell lines, L3.6p1 and Panc1 cells. We demonstrated in L3.6p1 cells as well as Panc1 cells that C6 liposomes, but not control liposomes, increased cytotoxicity, as measured by MTT assay. Moreover, the C6 liposome synergized with low dose gemcitabine, a first line pancreatic cancer neoplastic agent, to dramatically enhance apoptosis, as measured by caspase 3/7 activities. Further, in vitro transforming assays (soft agar colony forming assay) indicated that L3.6p1 cells treated with C6 liposome formed much smaller colonies than that of control cells, suggesting that the C6 liposome alone can inhibit the in vitro transforming ability of the L3.6p1 cells. Conclusions: Collectively, we have developed a novel nanotechnology-based liposomal drug delivery system for pancreatic tumors. Our data suggest that the C6 liposomal formulation is able to enhance the efficacy of gemcitabine to suppress the proliferation and in vitro transforming activity of pancreatic tumor cells. Acknowlegements: Penn State Research Foundation has licensed ceramide liposomes to Tracon Pharmaceutical, Inc. San Diego, CA. No significant financial relationships to disclose.
포스터 전시 : HELLP증후군에 의한 간파열
Authors: 나양원, 남창우, 임영철, 김규열, 최대화, 조홍래
Journal: Clinical and Molecular Hepatology (2003)

배경/목적: HELLP 증후군은 임산부 특히 자간전증(pre-eclampsia)을 동반한 임산부에게 발생할 수 있는 간 합병증으로 Hemolysis, Elevated Liver tests, and Low Platelets의 첫 글자를 따서 명명하였다. 용혈은 대개 잠재성이고 AST의 중앙치는 249 U/L, 혈소판수의 중앙치는 57,000/mm3라고 알려져 있다. 환자의 50%가 복통을 호소하여 가장 흔한 증상이고 그 외에 오심과 구토, 두통 등의 증상을 호소할 수 있다. 증상은 대개 임신 중에 발현하지만 약 30%의 환자는 분만 후에 증상을 나타낸다. 태아의 예후는 조산에 의해 결정되고 산모의 치사율은 1%정도로 대개 예후는 양호하지만 드물게 간괴사 혹은 간의 피막하 혈종과 파열에 의해 치명적인 경과를 밟을 수도 있다. 증례: 저자들은 비전형적인 자간전증을 보이던 29세 산모에게서 출산 후에 발생한 간의 피막하 혈종과 괴사 그리고 간 파열을 동반한 HELLP 증후군 1예를 치험하였다. 환자는 분만 2일전부터 심와부 동통 및 흉통을 호소하였다. 분만 직후 AST/ALT 7352/3512 U/L, 혈소판 수 55000/mm3 였고 CT에서 간 우엽 전체와 좌내구역 일부를 포함하는 괴사와 피막하혈종, 그리고 복강내 출혈의 소견을 보이며 쇼크상태에 이르러 간괴사와 간파열을 동반한 HELLP 증후군으로 진단하고 확대 간우엽절제수술을 시행하였다. 환자는 특별한 합병증 없이 3주후에 퇴원하여 외래 추적관찰 중에 있다.
Prognostic Factors in Feline Mammary Carcinoma
Authors: K Weijer, A A Hart
Journal: JNCI Journal of the National Cancer Institute (1983)

Feline mammary carcinoma and canine mammary cancer were evaluated as models for future experimental therapy. Those tumor characteristics known to be of special prognostic significance in human mammary cancers were tested for their prognostic significance in the cat and were compared with those in the dog. The statistical analysis presented is based on a prospective follow-up study of 202 cats treated surgically by mastectomy and by block dissection. Thirty-five factors (general, anamnestic, clinical and histologic data, and data on therapy) were analyzed for relationships with survival, with local recurrence, and with each other. Of the 17 significant relationships found between survival and the direct factors, only 7 remained significant after correction. The factors that related to survival independently of each other were age, diameter of the primary tumor, presence of tumor-positive lymph nodes as judged by microscopic examination, number of mitotic figures, necrosis of the primary tumor, and histologic verification of completeness of surgical treatment. The value of statistical analysis for use in prospective studies of human mammary cancer is discussed.
Progress in Chronic Lymphocytic Leukemia with Targeted Therapy
Authors: Wyndham H. Wilson
Journal: New England Journal of Medicine (2016)

For decades, the treatment of chronic lymphocytic leukemia (CLL) has relied on cytotoxic drugs with incremental benefit from anti-CD20 monoclonal antibodies. However, in the past 5 years, targeted drugs have fundamentally changed the management and outcome of CLL. In this issue of the Journal, two studies describe the use of second-generation drugs. In one of the studies, Byrd et al.1 target Bruton's tyrosine kinase (BTK) with the use of acalabrutinib, and in the other, Roberts et al.2 target B-cell lymphoma 2 protein (BCL2) with the use of venetoclax. In each case, the second-generation agents appear to improve substantially on . . .
In vitro and in vivo evaluation of novel implantation technology in hydrogel contact lenses for controlled drug delivery
Authors: Furqan A. Maulvi, Dhara H. Lakdawala, Anjum A. Shaikh, Ankita R. Desai, Harsh H. Choksi, Rutvi J. Vaidya, Ketan M. Ranch, Akshay R. Koli, Bhavin A. Vyas, Dinesh O. Shah
Journal: Journal of Controlled Release (2016)
원저 : 사염화탄소로 급성 간손상이 유발된 흰쥐에서 혈청 및 간조직의 Transforming Growth Factor-β1의 변화와 비타민 E의 효과
Authors: 이정일(Jung Il Lee), 이관식(Kwan Sik Lee), 정준표(Jun Pyo Chung), 박영년(Young Nyun Park), 이세준(Se Joon Lee), 한광협(Kwang Hyub Han), 전재윤(Chae Yoon Chon), 이상인(Sang In Lee), 문영명(Young Myoung Moon), 김현숙(Hyon Suk Kim)
Journal: Clinical and Molecular Hepatology (2000)

Background/Aims: The evaluation of the relationship between oxidative stress induced by acute carbon tetrachloride (CCl4) administration and transforming growth factor-β1 (TGF-β1), and the investigation of temporal patterns of serum alanine aminotransferase (ALT) and TGF-β1 expression which may clarify the pathogenesis of CCl4 induced liver injury and thus the mechanism of liver fibrogenesis. The aim of this study was to investigate TGF-β1 expression in rats with acute CCl4 injury and effect of vitamin E (vit. E) on TGF-β1 expression. Methods: Sixty male Sprague-Dawley rats had a single intraperitoneal injection of CCl4, of which 30 rats had daily intraperitoneal injection of vit. E, starting from 2 days before CCl4 treatment until the time of their sacrifice. The group of rats with CCl4 injection only was designated as group 1 and the group of rats with vit. E combined treatment was designated as group 2. Five rats from each group were sacrificed before and 8, 16, 32, 48, 60 hours after CCl4 injection, and their serum ALT, serum TGF-β1, and hepatic expression of TGF-β1 were examined. Results: The serum ALT levels were highest at 32 hours after CCl4 injection in both groups, serum TGF-β1 levels did not show any statistically significant changes after CCl4 injection in both groups, and TGF-β1 expression in the livers was highest at 32 hours after CCl4 injection in both groups. In the multiple regression analysis of vit. E's effect on serum ALT levels, serum TGF-β1 levels and hepatic TGF-β1 expression, only serum ALT level (p=0.049) and hepatic TGF-β1 expression (p=0.015) showed statistically significant suppression. Conclusion: Oxidative stress seems to play a role in the pathogenesis of hepatic fibrogenesis by increasing TGF-β1 expression in early acute liver damage. and vit. E may be effective in reducing acute liver injury and hepatic fibrogenesis.
(Korean J Hepatol 2000;6:147-155)
Prostatic acid phosphatase expression in human tissues
Authors: Thomas J. Graddis, Catherine J. McMahan, Jennifer Tamman, Keith J. Page, James B. Trager
Journal: Clinical Cancer Research (2010)

Abstract Introduction: Active cellular immunotherapy seeks to induce tumor-specific immunity in the patient and is consequently dependent on a suitable target tumor antigen. Sipuleucel-T is an autologous cellular immunotherapy that targets prostatic acid phosphatase (PAP), and has demonstrated evidence of survival prolongation in men with asymptomatic or minimally symptomatic metastatic castrate resistant prostate cancer in randomized clinical trials. PAP has been tested as a target antigen due to its high, and relatively specific, expression in the prostate. PAP expression in other human tissues was examined to help anticipate potential safety concerns associated with the development of immunity in this target. Methods: We used a variety of approaches to analyze PAP expression, including immunohistochemistry, in situ hybridization, and quantitative polymerase chain reaction. These laboratory-based techniques were complemented with an in silico analysis of reported PAP expression in human cDNA libraries. Results: Our studies confirmed that, while PAP expression is not restricted to prostate tissues, its expression in other human tissues is approx. 1 to 2 orders of magnitude less than that observed in the prostate. Conclusion: The relative specificity of PAP expression in prostate tissues supports its use in immunotherapies targeting prostate carcinoma. A greater knowledge of the expression of immunotherapy targets through a range of human cancers will better define appropriate clinical settings for their use; detailed assessment of their normal tissue distribution will aid the design of future clinical protocols for monitoring the safety of these potential therapeutic regimens.